Aldeyra Therapeutics
ALDX
77 hedge funds and large institutions have $103M invested in Aldeyra Therapeutics in 2019 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 32 increasing their positions, 18 reducing their positions, and 11 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
78% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 18
45% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 11
16% more capital invested
Capital invested by funds: $88.9M → $103M (+$14M)
7% more funds holding
Funds holding: 72 → 77 (+5)
2.18% more ownership
Funds ownership: 61.15% → 63.33% (+2.2%)
47% less call options, than puts
Call options by funds: $213K | Put options by funds: $405K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Prosight Management
Dallas,
Texas
|
+$3.69M |
| 2 |
Millennium Management
New York
|
+$1.53M |
| 3 |
Renaissance Technologies
New York
|
+$457K |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
+$375K |
| 5 |
Stifel Financial
St. Louis,
Missouri
|
+$307K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
-$3.59M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$2.42M |
| 3 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$487K |
| 4 |
Squarepoint
New York
|
-$325K |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$264K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PCA
76
Peddock Capital Advisors
Braintree,
Massachusetts
| $4K | +$4.34K | +752 | New |
|
|
UOC
77
UBS O'Connor
Chicago,
Illinois
| – | -$487K | -92,500 | Closed |
|
|
78
Squarepoint
New York
| – | -$325K | -61,695 | Closed |
|
|
DCM
79
DAFNA Capital Management
Los Angeles,
California
| – | -$264K | -50,000 | Closed |
|
|
FPC
80
Falcon Point Capital
San Francisco,
California
| – | -$140K | -25,118 | Closed |
|
81
D.E. Shaw & Co
New York
| – | -$95K | -18,111 | Closed |
|
|
JG
82
Jefferies Group
New York
| – | -$77K | -14,585 | Closed |
|
|
RJFSA
83
Raymond James Financial Services Advisors
St. Petersburg,
Florida
| – | -$71K | -13,500 | Closed |
|
84
Victory Capital Management
San Antonio,
Texas
| – | -$22K | -4,257 | Closed |
|
|
LC
85
Lindbrook Capital
Calabasas,
California
| – | -$16K | -3,000 | Closed |
|
|
TC
86
Truvestments Capital
Sarasota,
Florida
| – | -$5K | -936 | Closed |
|
87
Simplex Trading
Chicago,
Illinois
| – | -$3.36K | -581 | Closed |
|
ALDX Hedge Fund Activity: Q4 2019 in Review
77 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q4 2019, worth a combined $103M — up 16% from $88.9M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new ALDX positions and 11 closed out — a net gain of 5 holders — while 32 added to existing stakes and 18 trimmed.
The largest buyer was Prosight Management, adding an estimated $3.69M. The largest seller was 683 Capital Management, cutting an estimated $3.59M.
- 77 institutional investors held Aldeyra Therapeutics (ALDX) as of Q4 2019, up from 72 in Q3 2019.
- Funds reported $103M of Aldeyra Therapeutics stock for Q4 2019, up 16% quarter-over-quarter.
- 16 funds opened new Aldeyra Therapeutics positions in Q4 2019 and 11 closed out, a net change of +5 holders.
- The largest Aldeyra Therapeutics buyer in Q4 2019 was Prosight Management, an estimated $3.69M added.
- The largest Aldeyra Therapeutics seller in Q4 2019 was 683 Capital Management, an estimated $3.59M sold.
Based on aggregated 13F filings for Q4 2019.